Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9772894 | 1.00 | AOC3 (0.53) | AOC3GAALMNASMN1; SMN2SLC6A2 | |
| SCHEMBL9772644 | 1.00 | AOC3 (0.53) | AOC3GAALMNASMN1; SMN2SLC6A2 | |
| SCHEMBL11620920 | 0.94 | AOC3 (0.49) | AOC3GAALMNASMN1; SMN2SLC6A2 | |
| SCHEMBL24174177 | 0.89 | AOC3 (0.52) | AOC3GAALMNASMN1; SMN2SLC6A2 | |
| SCHEMBL6683963 | 0.89 | AOC3 (0.52) | AOC3GAALMNASMN1; SMN2SLC6A2 | |
| SCHEMBL21633858 | 0.89 | LMNA (0.48) | AOC3LMNASMN1; SMN2HTR1A | |
| SCHEMBL23588163 | 0.88 | AOC3 (0.50) | AOC3GAALMNASMN1; SMN2SLC6A2 | |
| SCHEMBL9814079 | 0.86 | AOC3 (0.49) | AOC3GAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6055300 | 0.84 | LMNA (0.41) | AOC3LMNASMN1; SMN2 | |
| SCHEMBL4839687 | 0.84 | AOC3 (0.47) | AOC3GAALMNASMN1; SMN2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912556-B | Synthesis method of alpha, beta-dicarbonyl-1, 2, 3-triazole compound | 武汉工程大学 | 2023-06-09 | — | — | CN | disclosed |
| EP-3704118-B1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-12 | — | — | EP | disclosed |
| CN-113912556-A | Synthetic method of alpha, beta-dicarbonyl-1, 2, 3-triazole compound | 武汉工程大学 | 2022-01-11 | — | — | CN | disclosed |
| WO-2019163946-A1 | PHYTOTOXICITY REDUCING AGENT CONTAINING BACTERICIDAL COMPOUND AS ACTIVE INGREDIENT, AND PHYTOTOXICITY-REDUCED HERBICIDAL COMPOSITION CONTAINING SAID PHYTOTOXICITY REDUCING AGENT AND HERBICIDAL COMPOUND | 三井化学アグロ株式会社 | 2019-08-29 | — | — | WO | disclosed |
| EP-2970155-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) | BRISTOL MYERS SQUIBB CO (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9675571-B2 | Inhibitors of indoleamine 2,3-dioxygenase (IDO) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-13 | — | — | US | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| EP-1436281-B1 | PIPERIDINE- AND PIPERAZINEACETAMIDES AS 17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORP (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7541365-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-0985649-B1 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6462248-B1 | THROUGH CONVERSION, ISOMERIZATION AND/OR ADSORPTIVE SEPARATION OF AROMATIC COMPOUNDS | TORAY INDUSTRIES, INC. (JP) | 2002-10-08 | — | — | US | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-5068432-A | Amination and etherification of a halo alcohol and resolution of a racemic mixture | ALDRICH CHEMICAL COMPANY, INC. (US) | 1991-11-26 | — | — | US | disclosed |
| US-4918242-A | Novel optically 1,3-phenoxypropylhalides | ALDRICH CHEMICAL COMPANY, INC. (US) | 1990-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | AOC3 3343/4885GAA 2975/4885LMNA 4640/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | AOC3 2019/4885GAA 3106/4885LMNA 4626/4885 |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | THPO, NFATC1, HPGDS | AOC3 40/4885GAA 1412/4885LMNA 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.